Gregg Gilbert
Stock Analyst at Truist Securities
(2.37)
# 2,304
Out of 4,814 analysts
91
Total ratings
53.7%
Success rate
5.38%
Average return
Main Sectors:
Stocks Rated by Gregg Gilbert
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DHT DHT Holdings | Maintains: Buy | $14 → $17 | $10.41 | +63.38% | 2 | Feb 16, 2024 | |
| COLL Collegium Pharmaceutical | Maintains: Buy | $31 → $37 | $26.94 | +37.34% | 1 | Jan 4, 2024 | |
| BMY Bristol-Myers Squibb Company | Reiterates: Buy | $84 | $49.23 | +70.65% | 9 | Sep 15, 2023 | |
| LLY Eli Lilly and Company | Maintains: Buy | $430 → $525 | $839.90 | -37.49% | 10 | Jul 20, 2023 | |
| EOLS Evolus | Maintains: Buy | $11 → $13 | $10.80 | +20.43% | 2 | Mar 4, 2022 | |
| NVCR NovoCure | Upgrades: Buy | n/a | $15.56 | - | 10 | Jan 20, 2022 | |
| MRK Merck & Co. | Maintains: Buy | $96 → $93 | $77.98 | +19.26% | 8 | Jun 7, 2021 | |
| ARQT Arcutis Biotherapeutics | Maintains: Buy | $38 → $48 | $13.01 | +268.95% | 2 | Feb 2, 2021 | |
| CHRS Coherus BioSciences | Initiates: Buy | $26 | $1.12 | +2,221.43% | 1 | Apr 17, 2020 | |
| MTNB Matinas BioPharma Holdings | Initiates: Buy | $150 | $0.57 | +26,448.67% | 1 | Jan 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $93 → $78 | $25.37 | +207.45% | 17 | Aug 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $76 → $78 | $148.66 | -47.53% | 5 | Feb 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $20 → $18 | $13.64 | +32.01% | 6 | Feb 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $105.28 | - | 7 | Nov 20, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $178 → $175 | $102.02 | +71.53% | 6 | Aug 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $65 → $66 | $173.00 | -61.85% | 4 | Jul 17, 2017 |
DHT Holdings
Feb 16, 2024
Maintains: Buy
Price Target: $14 → $17
Current: $10.41
Upside: +63.38%
Collegium Pharmaceutical
Jan 4, 2024
Maintains: Buy
Price Target: $31 → $37
Current: $26.94
Upside: +37.34%
Bristol-Myers Squibb Company
Sep 15, 2023
Reiterates: Buy
Price Target: $84
Current: $49.23
Upside: +70.65%
Eli Lilly and Company
Jul 20, 2023
Maintains: Buy
Price Target: $430 → $525
Current: $839.90
Upside: -37.49%
Evolus
Mar 4, 2022
Maintains: Buy
Price Target: $11 → $13
Current: $10.80
Upside: +20.43%
NovoCure
Jan 20, 2022
Upgrades: Buy
Price Target: n/a
Current: $15.56
Upside: -
Merck & Co.
Jun 7, 2021
Maintains: Buy
Price Target: $96 → $93
Current: $77.98
Upside: +19.26%
Arcutis Biotherapeutics
Feb 2, 2021
Maintains: Buy
Price Target: $38 → $48
Current: $13.01
Upside: +268.95%
Coherus BioSciences
Apr 17, 2020
Initiates: Buy
Price Target: $26
Current: $1.12
Upside: +2,221.43%
Matinas BioPharma Holdings
Jan 24, 2020
Initiates: Buy
Price Target: $150
Current: $0.57
Upside: +26,448.67%
Aug 10, 2018
Downgrades: Hold
Price Target: $93 → $78
Current: $25.37
Upside: +207.45%
Feb 16, 2018
Maintains: Hold
Price Target: $76 → $78
Current: $148.66
Upside: -47.53%
Feb 9, 2018
Maintains: Hold
Price Target: $20 → $18
Current: $13.64
Upside: +32.01%
Nov 20, 2017
Downgrades: Sell
Price Target: n/a
Current: $105.28
Upside: -
Aug 9, 2017
Maintains: Buy
Price Target: $178 → $175
Current: $102.02
Upside: +71.53%
Jul 17, 2017
Maintains: Hold
Price Target: $65 → $66
Current: $173.00
Upside: -61.85%